Inibidores da monoaminoxidase e cetamina intravenosa: uma associação segura?
DOI:
https://doi.org/10.25118/2763-9037.2022.v12.219Palavras-chave:
segurança, inibidores da monoaminoxidase, cetamina, pressão sanguíneaResumo
Introdução: A Cetamina emerge como uma droga rápida e efetiva no tratamento da Depressão Resistente ao Tratamento (DRT) e é a primeira droga com mecanismo de ação fora do sistema monoaminérgico aprovada para tal finalidade. Os pacientes com DRT, com frequência, estarão em uso, ou terão indicação de inibidores da monoaminoxidase (IMAOs). A cetamina tem efeitos simpaticomiméticos através, dentre outros mecanismos, de inibição da recaptura de noradrenalina; os riscos do uso concomitante dos IMAOs e de algumas drogas noradranérgicas já é estabelecido. Diante disto, a possibilidade de crises hipertensivas resultantes da combinação destes medicamentos requer atenção clínica. Objetivo: O objetivo desta revisão foi verificar aspectos importantes a respeito desta combinação, com enfoque na ocorrência de crises hipertensivas e outros efeitos cardiovasculares. Método: O estudo foi realizado através das bases de dados Pubmed, Scielo e Lilacs, datadas de 1990 até março de 2021, utilizando-se a combinação dos descritores: (Monoamine oxidase inhibitor) AND (Ketamine). Resultado: Os resultados demonstram segurança e eficácia da combinação, com elevações transitórias da frequência cardíaca e pressão arterial, sem consequências para os pacientes. Conclusão: Entretanto, tratam-se de dados de relatos e séries de casos e de uma pequena coorte retrospectiva. Portanto é possível que efeitos colaterais graves não sejam detectados nestas amostras por serem reduzidas.
Downloads
Métricas
Referências
Lacerda AL, Del Porto JA. Uso da cetamina no tratamento de transtornos psiquiátricos e dor crônica: teoria e prática. São Paulo: Editora dos editores; 2020.
Zhou YL, Liu WJ, Wang CY, Zheng W, Lan XF, Weng SY, Ning YP. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. Journal of Psychopharmacology. 2021;35(2):159-167 https://doi.org/10.1177/0269881120936909 DOI: https://doi.org/10.1177/0269881120936909
Liebe T, Shijia Li, Lord A, Colic L, Krause AL, Batra A, Kretzschmar MA, Sweeney-Reed CM, Behnisch G, Schott BH, Walter M. Factors influencing the cardiovascular response to subanesthetic ketamine: a randomized, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2017;20(11):909–918 https://doi.org/10.1093/ijnp/pyx055 DOI: https://doi.org/10.1093/ijnp/pyx055
Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ. Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. International Journal of Neuropsychopharmacol. 2021 Oct 23;24(10):808-831. https://doi.org/10.1093/ijnp/pyab039 - PMid:34170315 - PMCid:PMC8538895 DOI: https://doi.org/10.1093/ijnp/pyab039
Muntner N, Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge: Cambridge University Press; 2013. 620 p.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate Jr. CA, Stahl S. Synthesizing the evidence for Ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. American Journal of Psychiatry. 2021;178(5):383-99. https://doi.org/10.1176/appi.ajp.2020.20081251 PMid:33726522 DOI: https://doi.org/10.1176/appi.ajp.2020.20081251
Gaynes BN, Lux L, Gartlehner G, Asher G, Forman‐Hoffman V, Green J, Boland E, Weber RP, Randolph C, Bann C, Coker‐Schwimmer E, Viswanathan M, Lohr KN. Defining treatment‐resistant depression. Depression and Anxiety. 2019;37(2):134-45. https://doi.org/10.1002/da.22968 PMid:31638723 DOI: https://doi.org/10.1002/da.22968
Murphy JA, Sarris J, Byrne GJ. A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depression Research and Treatment. 2017:1-10. https://doi.org/10.1155/2017/4176825 - PMid:28840042 - PMCid:PMC5559917 DOI: https://doi.org/10.1155/2017/4176825
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. 2006;163(11):1905-17. https://doi.org/10.1176/ajp.2006.163.11.1905 PMid:17074942 DOI: https://doi.org/10.1176/ajp.2006.163.11.1905
Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. A consensus statement on the use of ketamine in the treatment of Mood disorders. JAMA Psychiatry. 2017;74(4):399. https://doi.org/10.1001/jamapsychiatry.2017.0080 PMid:28249076 DOI: https://doi.org/10.1001/jamapsychiatry.2017.0080
Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital. The Journal of Clinical Psychiatry. 2018;79(4). https://doi.org/10.4088/jcp.17m11731 - PMid:30063304 PMCid:PMC6296748 DOI: https://doi.org/10.4088/JCP.17m11731
Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. American Journal of Psychiatry. 2017;174(7):695-696. https://doi.org/10.1176/appi.ajp.2017.17020239 - PMid:28669202 PMCid:PMC5549850 DOI: https://doi.org/10.1176/appi.ajp.2017.17020239
Giakoumatos CI, Osser D. The Psychopharmacology Algorithm Project at the Harvard South Shore Program. Harvard Review of Psychiatry. 2019;27(1):33-52. https://doi.org/10.1097/hrp.0000000000000197 PMid:30614886 DOI: https://doi.org/10.1097/HRP.0000000000000197
Veraart JKE, Smith-Apeldoorn SY, Spaans HP, Kamphuis J, Schoevers RA. Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review. J Affect Disord. 2021;281:82-89. https://doi.org/10.1016/j.jad.2020.11.123 PMid:33307338 DOI: https://doi.org/10.1016/j.jad.2020.11.123
McIntyre RS, Carvalho IP, Lui LM, Majeed A, Masand PS, Gill H, Rodrigues NB, Lipsitz O, Coles AC, Yena L, Tamura JK, Iacobucci M, Lee P, Nasri F, Singhal N, Wong ER, Subramaniapillai M, Mansur R, Ho R, Lam RW, Rosenblat JD. The effect of intravenous, intranasal, and oral ketamine in Mood disorders: a meta-analysis. Journal of Affective Disorders. 2020;276:576-84. https://doi.org/10.1016/j.jad.2020.06.050 PMid:32871689 DOI: https://doi.org/10.1016/j.jad.2020.06.050
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American Journal of Psychiatry. 2018;175(2):150-8. https://doi.org/10.1176/appi.ajp.2017.17040472 PMid:28969441 PMCid:PMC5794524 DOI: https://doi.org/10.1176/appi.ajp.2017.17040472
Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M. Efficacy of eketamine augmentation in major depressive disorder. The Journal of Clinical Psychiatry. 2020;81(4). https://doi.org/10.4088/jcp.19r12889 DOI: https://doi.org/10.4088/JCP.19r12889
Culpepper L. Reducing the burden of difficult-to-treat major depressive disorder: revisiting monoamine oxidase inhibitor therapy. Prim Care Companion CNS Disord. 2013;81. https://doi.org/10.4088/PCC.13r01515 DOI: https://doi.org/10.4088/PCC.13r01515
Hopia H, Latvala E, Liimatainen L. Reviewing the methodology of an integrative review. Scandinavian Journal of Caring Sciences. 2016;30(4):662-9. https://doi.org/10.1111/scs.12327 - PMid:27074869 DOI: https://doi.org/10.1111/scs.12327
Whittemore R, Knafl K. The integrative review: updated methodology. Journal of Advanced Nursing. 2005;52(5):546-53. https://doi.org/10.1111/j.1365-2648.2005.03621.x - PMid:16268861 DOI: https://doi.org/10.1111/j.1365-2648.2005.03621.x
Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor. General Hospital Psychiatry. 2018;54:62-4. https://doi.org/10.1016/j.genhosppsych.2018.05.007 PMid:30100209 - PMCid:PMC6292194 DOI: https://doi.org/10.1016/j.genhosppsych.2018.05.007
Dunner DL. Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report. Neurology Psychiatry and Brain Research. 2020; 36:30-31. https://doi.org/10.1016/j.npbr.2020.02.008 DOI: https://doi.org/10.1016/j.npbr.2020.02.008
Doyle DJ. Ketamine induction and monoamine oxidase inhibitors. Journal of Clinical Anesthesia. 1990;2(5):324-5. Disponível em: https://doi.org/10.1016/0952-8180(90)90078-h DOI: https://doi.org/10.1016/0952-8180(90)90078-H
Bartova L, Vogl SE, Stamenkovic M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, Willeit M. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. European Neuropsychopharmacology. 2015;25(11):2183-4. https://doi.org/10.1016/j.euroneuro.2015.07.021 - PMid:26302763 DOI: https://doi.org/10.1016/j.euroneuro.2015.07.021
Wang JC, Swainson J. The concurrent treatment with intravenous ketamine and an irreversible monoamine oxidase inhibitor for Treatment-Resistant Depression without hypertensive crises. Journal of Clinical Psychopharmacology. 2020;40(5):515-7. https://doi.org/10.1097/JCP.0000000000001244 - PMid:32740556 DOI: https://doi.org/10.1097/JCP.0000000000001244
Bottemanne H, Bonnard E, Claret A, Petit AC, Gaillard R, Fossati P. Ketamine and monoamine oxidase inhibitor combination. Journal of Clinical Psychopharmacology. 2020;40(6):636-8. https://doi.org/10.1097/JCP.0000000000001281 - PMid:33009225 DOI: https://doi.org/10.1097/JCP.0000000000001281
Lu BY, Agapoff JR, Olson DJ, Williams SR, Roller A, Goebert D. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: a case series. Journal of Affective Disorders. 2020; 262:40-42. https://doi.org/10.1016/j.jad.2019.10.050 DOI: https://doi.org/10.1016/j.jad.2019.10.050
Ludwig VM, Sauer C, Young AH, Rucker J, Bauer M, Findeis H, Ritter P. Cardiovascular effects of combining subcutaneous or intravenous esketamine and the MAO inhibitor tranylcypromine for the treatment of depression: a retrospective cohort study. CNS Drugs. 2021; 35:881-892. https://doi.org/10.1007/s40263-021-00837-6 DOI: https://doi.org/10.1007/s40263-021-00837-6
Riva-Posse P, Reiff CM, Edwards JA, Job GP, Galendez GC, Garlow SJ, Saah TC, Dunlop BW, McDonald WM. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. Journal of Affective Disorders. 2018;236,291–297. https://doi.org/10.1016/j.jad.2018.02.025 DOI: https://doi.org/10.1016/j.jad.2018.02.025
van Haelst IMM, van Klei WA, Doodeman HJ, Kalkman CJ, Egberts TCG, MAOI Study Group. Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study. The Journal of Clinical Psychiatry. 2012;73(8):1103-1109. https://doi.org/10.4088/jcp.11m07607 - PMID: 22938842 DOI: https://doi.org/10.4088/JCP.11m07607
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Juliana Machado Leal dos Santos, Hugo Leonardo de Oliveira Couto, Dennison Carreiro Monteiro
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
